Drug profile · INN
sulfacytine
RENOQUID
sulfacytine (RENOQUID) is a dihydropteroate synthetase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — sulfacytine
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
sulfacytine (RENOQUID) is a dihydropteroate synthetase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Dihydropteroate synthetase inhibitor
Primary target: Dihydropteroate synthetase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Frequently asked questions
What is sulfacytine?
sulfacytine (RENOQUID) is a dihydropteroate synthetase inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for sulfacytine?
RENOQUID is a marketed brand name for sulfacytine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of sulfacytine?
sulfacytine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.